Agios Pharmaceuticals, Inc. (AGIO) Stock Grade

About Agios Pharmaceuticals, Inc.'s fundamentals

Agios Pharmaceuticals is a biotechnology company with a $2.0 billion market capitalization that demonstrated strong revenue growth of 48% year-over-year. However, the company operates at a significant loss, with a net margin of -764%, indicating it is spending substantially more than it generates in revenue. The company does not pay a dividend, and profitability metrics like P/E ratio and return on equity are not applicable due to the net loss reported in its latest annual statement.